Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
4257- CoQ10,    Dietary intake of coenzyme Q10 reduces oxidative stress in patients with acute ischemic stroke: a double-blind, randomized placebo-controlled study
- Trial, Stroke, NA
*MDA↓, *IL6↓, *SOD↑, *BDNF↑, *ROS↓, *Inflam↓, *neuroP↑,
6368- CPLE,    Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial
- Trial, Var, NA
PC↑,
6369- CPLE,    Carica papaya leaf extract (CPLE) versus placebo to improve chemotherapy induced thrombocytopenia (CIT): Results of a phase III triple blinded, randomized placebo controlled trial (PACT study).
- Trial, Var, NA
PC↑, other↝, CIT↓,
9274- CRAN,    Absorption, Metabolism and Excretion of Cranberry (Poly)phenols in Humans: A Dose Response Study and Assessment of Inter-Individual Variability
- Trial, Nor, NA
*Dose?, *BioAv↝, *BioAv↝,
3625- Cro,    Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial
- Trial, AD, NA
*Aβ↓, *cognitive↑,
3626- Cro,    Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial
- Trial, AD, NA
*cognitive↓,
3634- Cro,    A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease
- Trial, AD, NA
*cognitive↑,
7420- CS,    Beneficial effects of artichoke leaf extract supplementation on increasing HDL-cholesterol in subjects with primary mild hypercholesterolaemia: a double-blind, randomized, placebo-controlled trial
- Trial, Obesity, NA
*LDL↓, *HDL↑, Dose↝,
7417- CS,  CGA,    Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans
- Trial, Nor, NA
Dose↝, BioAv↝, Half-Life↝,
7419- CS,    Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial
- Trial, Nor, NA
*Dose↝, *other↓,
7421- CS,    Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial
- Trial, Nor, NA
*hepatoP↑, *Dose↝, *toxicity↓, *BloodF↑, *ALAT↓, *AST↓, *Bil↓, *LDL↓, *HDL↓, *TG/TAG↓,
3577- CUR,    Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
- Trial, AD, NA
*cognitive∅, *BioAv↑,
6226- CUR,  Rad,    Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial
- Trial, Cerv, NA
survivin↓, RadioS↑, toxicity↓,
6208- CUR,    Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial
- Trial, Nor, NA
*memory↑, *Aβ↓, *tau↓,
6238- CUSP9,    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
- Trial, GBM, NA
toxicity↓, TrxR↓, ROS↓, TumCI↓, TumCMig↓, TumCA↓, MMP2↓, MMP9↓, COX2/PTGS2↓, ALDH↓, TumAuto↑, P-gp/ABCB1↓, eff↑,
6241- CUSP9,    RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4
- Trial, GBM, NA
eff↑,
9097- CV,    Beneficial immunostimulatory effect of short-term Chlorella supplementation: enhancement of natural killer cell activity and early inflammatory response (randomized, double-blinded, placebo-controlled trial)
- Trial, Nor, NA
*Dose↝, *IFN-γ↑, *NK cell↑,
9108- CV,    The influence of chlorella and its hot water extract supplementation on quality of life in patients with breast cancer
- Trial, BC, NA
Dose↝, fatigue↓, QoL↑, Ingr↝, Dose↝, Perforin↑,
9109- CV,    Salivary secretory immunoglobulin A secretion increases after 4-weeks ingestion of chlorella-derived multicomponent supplement in humans: a randomized cross over study
- Trial, Nor, NA
*Dose↝, *IgA↑, *Imm↑,
6262- Cyste,    A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety
- Trial, Nor, NA
*eff↑,
6260- Cyste,    A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
- Trial, Nor, NA
*toxicity↓,
6592- DAS,    Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- Trial, CML, NA
Dose↝, other↝, OS↑,
6679- DCA,    GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial
- Trial, Melanoma, NA
PDK1 / PDPK1↓, Half-Life↝, eff↑, NP/CIPN↑, Dose↝, Half-Life↝,
6678- DCA,  Cisplatin,    Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
- Trial, HNSCC, NA
PDK1 / PDPK1↓, OS∅, lactateProd↓, toxicity↝, FAO↑,
6749- DHA,    The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
- Trial, BC, NA
*IFN-γ↑, *TNF-α↑, Imm↑,
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, *NLR↓, eff↑, *IL4↑, *IL10↑, *IFN-γ↑, *TNF-α↑, Imm↑, eff↑, TumW↓,
6751- DHA,    Exploratory outcomes of the DHA WIN randomized controlled trial: Supplementing women with docosahexaenoic acid did not reduce the impact of neoadjuvant breast cancer chemotherapy on quality of life or exercise behaviour
- Trial, BC, NA
QoL∅,
6752- DHA,    A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
- Trial, BC, NA
TNF-α∅, IL1β∅, COX2/PTGS2∅,
6753- DHA,    Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting (DHA-WIN)
- Trial, BC, NA
ChemoSen↑, TumCG↓, Weight↑, chemoP↑, Dose↝,
6754- DHA,    Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
- Trial, AD, NA
*DHA↑, *eff↝, *BrainVol∅, *cognitive∅,
6755- DHA,    Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia
- Trial, AD, NA
*other↝,
6758- DHA,  Chemo,    Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
- Trial, BC, NA
ChemoSen↑, selectivity↑, ROS↑, *toxicity↓, Dose↝,
6760- DHA,    Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
- Trial, Nor, NA
*BP↓, *eff↝,
6761- DHA,    Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women
- Trial, Nor, NA
*BP↓,
6711- dietF,    Gut-microbiota-targeted diets modulate human immune status
- Trial, Nor, NA
*GutMicro↑, *Inflam↓, *Imm↑, *Obesity↓, *AntiDiabetic↑, *AntiCan↑, *cardioP↑, *IL6↓, *IL10↓, *IL12↓,
1848- dietFMD,  Chemo,    Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
- Trial, BC, NA
ChemoSideEff↓, ChemoSen↑, eff↑,
1855- dietFMD,    Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study
- Trial, Var, NA
ChemoSideEff↓, QoL↑, IGF-1↓, Insulin↓,
1862- dietFMD,    Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
- Trial, Var, NA
OS↑,
1842- dietFMD,    Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment
- Trial, Var, NA
Strength∅, Weight∅, IGF-1↓, IGFBP3↑, IGFBP1↑, eff↑,
1841- dietFMD,    Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
- Trial, Var, NA
BG↓, AntiCan↑, IFN-γ↑, eff↑, Dose↝, CD14↓, IGF-1↓, IGFR↓, CD8+↑, NK cell↑,
5193- dietMet,  Rad,    A Phase I Trial of a Methionine Restricted Diet with Concurrent Radiation Therapy
- Trial, Var, NA
toxicity↝, other↝,
2160- dietP,    Dietary proteins and protein sources and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study
- Trial, Heart, NA
Risk↓,
2165- dietP,  SFN,    Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study
- Trial, PC, NA
Dose↝, OS↑, eff↝,
2154- dietP,  Ex,    American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)
- Trial, Colon, NA
OS↑,
8835- DIM,    Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN: implications for cervical cancer prevention
- Trial, Cerv, NA
Dose↝, eff↑,
8834- DIM,    Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial
- Trial, Cerv, NA
AntiTum↑, Dose↝, toxicity↓, eff↓,
8830- DIM,  Tam,    A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
- Trial, BC, NA
Dose?, 2/16-OHE1↓, SHBG↑,
8832- DIM,    Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy
- Trial, Pca, NA
Dose?, *toxicity↓, BioAv↑, 2/16-OHE1↝, eff↝,
8833- DIM,    A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer
- Trial, Pca, NA
AR↓, PSA↓, Dose↝, BioAv↝, toxicity↓, toxicity↝, Dose↝, QoL↝,
6729- Dipy,    Dipyridamole prevents triple-negative breast-cancer progression
- Trial, BC, MDA-MB-231
TumCG↓, TumMeta↑, β-catenin/ZEB1↓, *AntiAg↑, TumCCA↑, Wnt↓, NF-kB↓,

Showing Research Papers: 101 to 150 of 542
Prev Page 3 of 11 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 542

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Bil∅, 1,   Copper↓, 2,   CoQ10↑, 1,   GSH↓, 1,   MDA↓, 1,   ROS↓, 3,   ROS↑, 5,   ROS↝, 2,   SOD↑, 1,   TrxR↓, 1,   VitC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

selm↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   Insulin↓, 2,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 1,   FAO↑, 1,   lactateProd↓, 1,   PDK1 / PDPK1↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 8,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Cyt‑c↝, 1,   IAP1↓, 1,   Mcl-1↓, 3,   NOXA↑, 1,   Perforin↑, 1,   PUMA↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

ADCY4↑, 1,   p‑Akt↓, 1,   EGFR↓, 3,   IGF-2R↑, 1,   IGFR↓, 1,   PI3K↓, 1,   PTEN↑, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

HDAC↓, 4,   miR-106b↓, 1,   miR-19b↓, 1,   miR-29b↑, 1,   miR-30a-5p↑, 1,   Myc↓, 1,   other?, 1,   other↓, 4,   other↑, 6,   other↝, 24,   other∅, 3,   SD↑, 5,   SD↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

NEU1↑, 1,   TumAuto↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

8-oxo-dG↓, 1,   NKX3.1↓, 1,   P53↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cellSen?, 1,   cycD1/CCND1↓, 2,   Ki-67↓, 6,   P21↑, 3,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CSCs↓, 2,   HH↓, 3,   HH∅, 1,   IGF-1↓, 7,   IGF-1↑, 1,   IGFBP1↑, 2,   IGFBP3↓, 1,   IGFBP3↑, 1,   JAG1↑, 1,   Ki-67↓, 6,   NOTCH3↑, 1,   Smo↓, 1,   TumCG↓, 9,   TumCP↓, 11,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↝, 1,   AntiAg∅, 1,   Ca+2↓, 1,   Ca+2↑, 1,   GLI3↓, 1,   MMP2↓, 1,   MMP9↓, 2,   MMP9:TIMP1↑, 1,   Slug↓, 2,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   TumCA↓, 3,   TumCI↓, 3,   TumCMig↓, 3,   TumMeta↓, 2,   TumMeta↑, 1,   TumMeta∅, 1,   Twist↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   angioG∅, 1,   E-sel↓, 1,   Endoglin↓, 1,   Hif1a↓, 2,   PGI2↓, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,   MPT↑, 1,   TRPV1↑, 1,   ZO-1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ALC↓, 1,   ANXA1↓, 1,   CD14↓, 1,   CD25+↓, 1,   CD4+↓, 1,   CD4+↑, 3,   CD8+↑, 5,   COX2/PTGS2↓, 4,   COX2/PTGS2∅, 1,   Eos↑, 1,   FoxP3+↓, 1,   Gal-3?, 1,   Gal-3↓, 1,   GM-CSF↓, 1,   IFN-γ↑, 2,   IL10↓, 1,   IL10↑, 1,   IL12↓, 1,   IL18↑, 1,   IL1β↓, 2,   IL1β∅, 1,   IL2↑, 1,   IL22↓, 1,   IL6↓, 4,   Imm↑, 12,   Imm⇅, 1,   Imm↝, 1,   INF-γ↝, 1,   Inflam↓, 9,   LIF↑, 1,   MCP1/CCL2↓, 1,   Neut↓, 1,   Neut↑, 2,   NF-kB↓, 4,   NK cell↑, 4,   PDT+↓, 1,   PGE2↓, 2,   PSA↓, 16,   T-Cell↑, 1,   TNF-α↓, 2,   TNF-α↑, 1,   TNF-α∅, 1,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↓, 1,   TrkB↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↓, 1,   2/16-OHE1↑, 1,   2/16-OHE1↝, 1,   ADRB2↓, 1,   AR↓, 3,   AR↝, 1,   DHT↓, 1,   ENL↑, 1,   EstroRS/ERS↑, 1,   PPARγ↓, 1,   SHBG↑, 1,   testos↓, 1,   testos∅, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 10,   BioAv↝, 10,   BioEnh↑, 1,   ChemoSen↑, 8,   ChemoSen∅, 1,   CYP1A2↑, 1,   CYP3A4⇅, 1,   Dose?, 13,   Dose↓, 3,   Dose↑, 7,   Dose↝, 152,   Dose∅, 4,   eff↓, 3,   eff↑, 40,   eff↝, 8,   eff∅, 12,   Half-Life↑, 1,   Half-Life↝, 6,   P-gp/ABCB1↓, 2,   RadioS↑, 5,   selectivity↑, 5,   Synergy?, 1,   Synergy↑, 10,   Synergy∅, 1,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALB∅, 1,   AR↓, 3,   AR↝, 1,   AST↓, 1,   BG↓, 1,   Bil∅, 1,   BUN↓, 1,   CA125↓, 1,   CA125∅, 1,   CA19-9↓, 1,   CEC↝, 1,   CIT↓, 1,   creat↓, 1,   CRP↓, 3,   CRP∅, 1,   CTC↓, 1,   EGFR↓, 3,   EstroRS/ERS↑, 1,   HemoG↑, 1,   IL6↓, 4,   Myc↓, 1,   Mye↓, 1,   NLR↓, 1,   PC↑, 3,   Polyps↓, 1,   PSA↓, 16,   PSADT↓, 1,   PSADT↑, 3,   RBC↑, 4,   UFR↑, 1,   Verbal↑, 2,   VitD↑, 1,   WBC↑, 2,  

Functional Outcomes(tgid=23) ⓘ

AEs∅, 1,   AntiCan↓, 1,   AntiCan↑, 6,   antiD↑, 4,   antiNeop↑, 2,   AntiTum↑, 4,   AntiTum∅, 1,   ANXi↓, 4,   APG↓, 2,   cachexia↓, 1,   cardioP↑, 4,   CardioT↑, 1,   CardioT↝, 1,   chemoP↑, 8,   chemoP∅, 1,   chemoPv↑, 5,   ChemoSideEff↓, 2,   cognitive↑, 1,   cognitive∅, 1,   CR↑, 5,   DCR↑, 5,   DCR↝, 1,   fatigue↓, 5,   fatigue∅, 1,   hepatoP↓, 1,   hepatoP↑, 2,   LC↑, 1,   mal↓, 1,   memory↑, 2,   Mood↑, 1,   Mucositis↓, 5,   Nausea↓, 4,   Nausea∅, 2,   neuroP↑, 1,   NP/CIPN↓, 2,   NP/CIPN↑, 3,   Obesity↓, 1,   ORR↑, 4,   ORR∅, 1,   OS?, 1,   OS↑, 55,   OS↝, 1,   OS∅, 11,   Pain↓, 9,   PFS?, 1,   PFS↑, 9,   PFS∅, 1,   QoL↑, 21,   QoL↝, 1,   QoL∅, 4,   radioP?, 1,   radioP↑, 5,   radioP↝, 1,   Remission↑, 3,   RFS↑, 1,   Risk↓, 14,   Risk↑, 2,   Risk↝, 2,   Risk∅, 6,   stomatitis↓, 1,   Strength↑, 1,   Strength∅, 1,   Stress↓, 1,   toxicity↓, 29,   toxicity↑, 1,   toxicity↝, 26,   toxicity∅, 1,   TTP↑, 1,   TumVol↓, 4,   TumW↓, 1,   Vomit↓, 4,   Vomit∅, 2,   Weight↑, 6,   Weight∅, 2,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Diar↓, 1,   Diar⇅, 1,   GutMicro↑, 3,   Inf↓, 4,   Sepsis↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↑, 1,   Ingr↝, 4,  
Total Targets: 317

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,   NA↑, 1,   NA↝, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 2,   antiOx↑, 12,   Bil↓, 2,   Bil∅, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 5,   HDL↓, 2,   HDL↑, 4,   HO-1↑, 1,   Iron↓, 1,   Iron↑, 1,   lipid-P↓, 2,   MDA↓, 4,   MDA↑, 1,   MPOD↑, 2,   NRF2↑, 2,   PCO↓, 1,   ROS↓, 17,   SAM-e↓, 1,   SOD↑, 3,   TAC↑, 6,   TBARS↓, 1,   uricA↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↓, 1,   mitResp↑, 1,   mtDam↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12-HETE↓, 1,   5-HETE↓, 1,   ACLY↓, 1,   AcOH↑, 2,   adiP↑, 1,   ALAT↓, 6,   ALAT↑, 1,   ALAT∅, 2,   AMPK↑, 1,   Buty↑, 4,   CRM↑, 1,   DHA↑, 2,   Eic↓, 1,   FFA/NEFA↓, 1,   FFA/NEFA↝, 1,   glucose↓, 1,   glucose∅, 1,   KeyT↝, 1,   lactateProd↓, 1,   LDL↓, 11,   lipidLev↓, 1,   NH3↓, 1,   PA↑, 2,   SCFAs↑, 3,   SCFAs∅, 1,   SIRT1↑, 1,   Uridine↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3↓, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CK2↓, 1,   PI3K↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 3,   DNMT3A↑, 1,   HDAC3↓, 1,   other?, 3,   other↓, 4,   other↑, 18,   other↝, 20,   other∅, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNArepair↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Choline↑, 1,   Diff↝, 1,   EP2↑, 1,   IGF-1↓, 1,   IGF-1↑, 1,   IGFBP3↓, 1,   NOTCH↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 5,   AntiAg∅, 1,   MMP9↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   TXA2↓, 1,   VCAM-1↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   COX1↓, 1,   Eos↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 5,   IgA↑, 1,   IgE↓, 1,   IL1↓, 1,   IL10↓, 2,   IL10↑, 1,   IL10∅, 1,   IL12↓, 1,   IL17∅, 1,   IL1β↓, 6,   IL4↑, 1,   IL4∅, 1,   IL6↓, 12,   IL8↓, 1,   Imm↑, 7,   Inflam↓, 26,   IP-10/CXCL-10↓, 1,   MCP1/CCL2↓, 1,   MCP1/CCL2↝, 1,   MIP‑1α/CCL3?, 1,   NF-kB↓, 1,   NK cell↑, 5,   PGE2↓, 2,   PGE2∅, 1,   PSA↓, 1,   TNF-α↓, 9,   TNF-α↑, 3,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5-AR↓, 1,   5HT↑, 3,   Ach↑, 2,   AChE↓, 5,   BDNF↑, 8,   BDNF∅, 1,   proBDNF↑, 1,   BrainVol↑, 1,   BrainVol↝, 1,   BrainVol∅, 3,   GABA↑, 1,   NGF↑, 2,  

Protein Aggregation(tgid=19) ⓘ

APOE4↑, 1,   Aβ↓, 10,   Aβ∅, 1,   BACE/β-secretase↓, 1,   tau↓, 3,   p‑tau↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↑, 1,   cortisol↓, 1,   END↑, 1,   ENL↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 22,   BioAv↝, 14,   Dose?, 20,   Dose↓, 1,   Dose↑, 8,   Dose↝, 143,   eff↓, 2,   eff↑, 20,   eff↝, 8,   eff∅, 1,   Half-Life↓, 2,   Half-Life↑, 2,   Half-Life↝, 20,   P450↓, 1,   Synergy↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

ADC↓, 1,   ALAT↓, 6,   ALAT↑, 1,   ALAT∅, 2,   ALB↑, 3,   ALP↓, 1,   AST↓, 4,   AST↑, 1,   AST∅, 2,   Bil↓, 2,   Bil∅, 1,   BloodF↑, 4,   BMD↑, 1,   BP↓, 12,   BP∅, 2,   Calcium↑, 1,   CCr / CrCl↓, 1,   CCr / CrCl∅, 1,   creat∅, 1,   CRP↓, 5,   FEV1↑, 2,   Hcy/homoC↓, 13,   Hcy/homoC↝, 1,   HemoG↑, 2,   HRV↑, 1,   hs-CRP↓, 2,   IL6↓, 12,   IRes↓, 1,   KeyT↝, 1,   LDH↓, 3,   NLR↓, 1,   PC∅, 1,   PEF↑, 1,   PSA↓, 1,   rHR↓, 1,   TC↓, 3,   TG/TAG↓, 3,   TMAO∅, 1,   UFR?, 1,   UFR↑, 1,   UR↓, 1,   Verbal↑, 2,   VitD↑, 1,   WBC∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   antiAll↑, 2,   AntiCan↑, 2,   antiD↑, 3,   AntiDiabetic↑, 2,   AntiTum↑, 3,   ANXi↓, 5,   BDI↓, 1,   BowelM↑, 1,   cardioP↑, 6,   chemoP↑, 3,   cognitive?, 1,   cognitive↓, 1,   cognitive↑, 78,   cognitive↝, 2,   cognitive∅, 12,   fatigue↓, 2,   GFR↓, 1,   GFR∅, 1,   hepatoP↑, 8,   IPSS↓, 1,   IPSS↝, 1,   Learn↑, 1,   memory↑, 26,   memory∅, 1,   Mood↑, 10,   motorD↑, 13,   MusCon↓, 1,   neuroP↑, 13,   NMSS↓, 1,   Obesity↓, 3,   OS↑, 1,   Pain↓, 12,   QoL?, 1,   QoL↑, 13,   RenoP↑, 3,   Risk↓, 6,   Risk↑, 2,   Risk↝, 1,   RT↓, 2,   Sleep↑, 12,   Strength↑, 4,   Stress↓, 6,   Tinn↓, 1,   toxicity↓, 40,   toxicity↑, 1,   toxicity↝, 4,   toxicity∅, 7,   UPDRS↓, 1,   UPDRSIII∅, 1,   Weight↓, 1,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 2,   AntiFungal↑, 2,   AntiViral↑, 4,   Bacteria↓, 2,   GutMicro↑, 10,   GutMicro∅, 1,   Inf↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 8,  
Total Targets: 266

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page